India's biotechnology landscape has transformed dramatically, with the number of startups increasing from approximately 500 in 2018 to over 10,000 by 2025. This growth is supported by government initiatives like the BioE3 Policy and a vision for a $300-billion bioeconomy by 2030. Established companies have demonstrated India's capabilities in affordable vaccines and generics, while startups leverage AI for advancements in drug discovery and diagnostics. However, the sector faces critical challenges, including a lack of funding for scaling operations and fragmented infrastructure that complicates development processes. Regulatory complexities further delay progress, deterring international collaboration. To sustain growth, India must consolidate resources, bridge financing gaps, and streamline regulatory frameworks, ensuring that its biotech sector can compete globally and deliver impactful healthcare solutions.